Skip to main content
. 2023 Jul 17;8(7):370. doi: 10.3390/tropicalmed8070370

Table 3.

Information relating to use of HCV drugs across Caribbean islands.

List of Caribbean Countries Comments
Antigua and Barbuda -----------
Aruba Routine use of Epclusa (sofosbuvir/velpatasvir 400/100)
Bahamas
  • -

    In the private sector, patients are treated with Epclusa (sofosbuvir/velpatasvir 400/100) and Harvoni (ledipasvir/sofosbuvir 90/400)
Barbados
  • -

    Epclusa (sofosbuvir/velpatasvir 400/100) is supplied if needed for treatment of HCV-infected patient (s)
Bermuda Harvoni (ledipasvir/sofosbuvir 90/400)
Curacao Routine use of Epclusa (sofosbuvir/velpatasvir 400/100)
Virgin Islands Currently no cases of hepatitis C
Guyana Discontinued use of Epclusa (sofosbuvir/velpatasvir 400/100) and current use of cheaper combination (daclatasvir/velpatasvir)
Jamaica
  • -

    Use of Epclusa (sofosbuvir/velpatasvir 400/100) and Harvoni (ledipasvir/sofosbuvir 90/400) for those with age more than 6 years—ordered from USA/through local distributor
Saint Lucia Currently no cases of hepatitis C on the island
Saint Maarten Routine use of Epclusa (sofosbuvir/velpatasvir 400/100)
The protocol members of the Organisation of Eastern Caribbean States (OECS) are

  • Antigua and Barbuda

  • Commonwealth of

  • Dominica

  • Grenada

  • Montserrat

  • St. Kitts and Nevis

  • Saint Lucia

  • St. Vincent and

  • the Grenadinesines.

The associate members of the OECS are:

  • The British Virgin Islands

  • Anguilla

  • Martinique

  • Guadeloupe.

 One patient for the period 2020–2022 received Epclusa (sofosbuvir/velpatasvir 400/100)

There are limited data available on treatment for HCV in the Caribbean. A dashed line indicates that no information is available for that country. Data were collected via a mini survey from members of the Caribbean Association of Pharmacists (CAP). Members responded via email or ‘WhatsApp’. Abbreviations: HCV, hepatitis C.